Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab Beta Maintenance in Chinese Patients with High-Risk Neuroblastoma
NCT05373901Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Dinutuximab beta in neuroblastoma, sponsored by BeiGene. Primary endpoints: Number of Participants With Adverse Events, Area Under the Serum Concentration-time Curve From Zero to Last Measurable Concentration and 7 more. Started Jun 2022; status: completed.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05373901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373901.